Literature DB >> 22038260

Cardiorenal connection in chronic kidney disease.

Sadayoshi Ito1.   

Abstract

Chronic kidney disease (CKD), as defined by reduced glomerular filtration rate (<60 ml/min/1.73 m(2)) and/or the presence of renal damage for >3 months, is a significant threat for public health in modern societies. Recent epidemiological studies have demonstrated that CKD is a significant risk for cardiovascular events independently of classical risk factors such as hypertension, dyslipidemia and diabetes. The mechanisms by which CKD increases the risk of cardiovascular events are currently under intensive investigation. Among various components of CKD, microalbuminuria is of particular interest, because it is a significant risk factor not only in diabetic and hypertensive subjects but also in the general population. Microalbuminuria is also closely associated with salt sensitivity of blood pressure, and the salt sensitivity is an independent risk factor for cardiovascular disease even in normotensive subjects. Several factors are likely to be involved in such associations, including the renin-angiotensin system (RAS), oxidative stress and inflammation. In addition, there may be more specific hemodynamic mechanisms in the kidney and other vital organs underlying these associations. This review describes 'the strain vessel hypothesis' as a possible mechanism for cerebrocardiorenal connections. In addition we discuss the significance of underlying diseases as cardiovascular risks of CKD as well as the role of RAS inhibition in the management of CKD patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038260     DOI: 10.1007/s10157-011-0493-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  64 in total

1.  Large artery stiffening as a link between cerebral lacunar infarction and renal albuminuria.

Authors:  Junichiro Hashimoto; Tomoyuki Aikawa; Yutaka Imai
Journal:  Am J Hypertens       Date:  2008-09-18       Impact factor: 2.689

2.  Usefulness of RAS inhibition depends on baseline albuminuria.

Authors:  Sadayoshi Ito
Journal:  Nat Rev Nephrol       Date:  2010-01       Impact factor: 28.314

3.  Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex.

Authors:  B M Iversen; K Amann; F I Kvam; X Wang; J Ofstad
Journal:  Am J Physiol       Date:  1998-02

4.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

5.  Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity.

Authors:  H L Hillege; W M Janssen; A A Bak; G F Diercks; D E Grobbee; H J Crijns; W H Van Gilst; D De Zeeuw; P E De Jong
Journal:  J Intern Med       Date:  2001-06       Impact factor: 8.989

6.  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Authors:  Folkert W Asselbergs; Gilles F H Diercks; Hans L Hillege; Ad J van Boven; Wilbert M T Janssen; Adriaan A Voors; Dick de Zeeuw; Paul E de Jong; Dirk J van Veldhuisen; Wiek H van Gilst
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

7.  Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension.

Authors:  E Eng; M Veniant; J Floege; J Fingerle; C E Alpers; J Menard; J P Clozel; R J Johnson
Journal:  Am J Hypertens       Date:  1994-02       Impact factor: 2.689

8.  Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.

Authors:  Danilo Fliser; Konrad Buchholz; Hermann Haller
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

9.  Role of salt sensitivity, blood pressure, and hyperinsulinemia in determining high upper normal levels of urinary albumin excretion in a healthy adult population.

Authors:  Luigi X Cubeddu; Irene S Hoffmann; Lisette M Aponte; Rosaura Nuñez-Bogesits; Helimenia Medina-Suniaga; Magaly Roa; Robert S Garcia
Journal:  Am J Hypertens       Date:  2003-05       Impact factor: 2.689

Review 10.  The heart, macrocirculation and microcirculation in hypertension: a unifying hypothesis.

Authors:  Harry A J Struijker Boudier; Géraldine M S Cohuet; Marcus Baumann; Michel E Safar
Journal:  J Hypertens Suppl       Date:  2003-06
View more
  7 in total

Review 1.  Diabetes and its comorbidities--where East meets West.

Authors:  Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan
Journal:  Nat Rev Endocrinol       Date:  2013-05-28       Impact factor: 43.330

Review 2.  Angiotensin II blockade and renal protection.

Authors:  Hiroyuki Kobori; Hirohito Mori; Tsutomu Masaki; Akira Nishiyama
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.

Authors:  Hiroko Suzuki; Kazuyoshi Okada; Masanori Abe; Noriaki Maruyama; Yoshinori Yoshida; Seishiro Baba; Hiroyuki Takashima; Masayoshi Soma
Journal:  Clin Exp Nephrol       Date:  2012-11-09       Impact factor: 2.801

4.  ACE-inhibition increases podocyte number in experimental glomerular disease independent of proliferation.

Authors:  Jiong Zhang; David Yanez; Anna Floege; Julia Lichtnekert; Ronald D Krofft; Zhi-Hong Liu; Jeffrey W Pippin; Stuart J Shankland
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-08-20       Impact factor: 1.636

5.  Moderately increased albuminuria, chronic kidney disease and incident dementia: the HUNT study.

Authors:  Jessica Mira Gabin; Solfrid Romundstad; Ingvild Saltvedt; Jostein Holmen
Journal:  BMC Nephrol       Date:  2019-07-12       Impact factor: 2.388

Review 6.  "Greedy Organs Hypothesis" for sugar and salt in the pathophysiology of non-communicable diseases in relation to sodium-glucose co-transporters in the intestines and the kidney.

Authors:  Hiroshi Itoh; Masami Tanaka
Journal:  Metabol Open       Date:  2022-02-09

7.  T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease.

Authors:  Masanori Abe; Kazuyoshi Okada; Hiroko Suzuki; Yoshinori Yoshida; Masayoshi Soma
Journal:  BMC Nephrol       Date:  2013-07-01       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.